secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMICUS THERAPEUTICS, INC. (—)
CIK:        0001178879
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001140361-26-016968
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amicus Therapeutics acquired by BioMarin for $14.50 per share in all-cash merger
--------------------------------------------------------------------------------

- Merger completed on April 27, 2026; Amicus shareholders receive $14.50 per share in cash.
- Company Common Stock will be suspended from trading on Nasdaq effective April 28, 2026.
- All outstanding equity awards were cancelled and converted into cash payments based on the merger consideration.
- Entire board of directors and executive officers resigned; new directors and officers from BioMarin appointed.
- Amicus repaid and terminated its October 2023 loan agreement with Blackstone and other lenders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/0001140361-26-016968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/ef20071351_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-016968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer